Home » Icagen Finishes Dose Trial for Asthma Drug
Icagen Finishes Dose Trial for Asthma Drug
Icagen has completed its Phase I multiple-ascending dose trial of senicapoc for the treatment of asthma.
The drug was well tolerated at all tested doses and exhibited pharmacokinetics consistent with once-daily dosing. No serious adverse events were reported, and no patients withdrew from the study. There were no dose-limiting toxicities in any subject.
The company said it expects to initiate a Phase II proof-of-concept clinical trial during the second half of the year.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May